- Details
- Hikmat Al-Ahmadie and Olivier Elemento join Ashish Kamat to discuss the data on artificial intelligence in cancer, with specific reference to bladder cancer. The discussion includes an overview of the benefits of using AI and deep machine learning to predict tumor types, responses, and diagnoses. The conversation addresses how automation and digitization intersect well with pathology. However, cur...
|
- Details
- Nicholas James joins Alicia Morgans in a discussion of the first results of the novel BladderPath trial examining the role of magnetic resonance imaging (MRI) for bladder cancer staging. BladderPath is a randomized comparison of the time from the initial diagnosis to “correct” treatment among patients with possible muscle-invasive bladder cancer who receive staging with MRI, compared to TURBT. Nic...
|
- Details
- Tamer Aboushwareb, Vice President of Medical Affairs, Pacific Edge, Ltd provides an overview of the Cxbladder Detect urine-based cancer diagnostic test and is joined by Neal Shore and Josh Meeks for a discussion on the clinical implications of the use of this test which is designed for high-risk patients who present with hematuria. Cxbladder is a suite of non-invasive, urine-based laboratory tests...
|
- Details
- Ashish Kamat converses with Patrick Hensley of the University of Kentucky about his 2022 John Quale Travel Award. Dr. Hensley dives deep into his research, which aims to refine patient selection for neoadjuvant chemotherapy for muscle-invasive bladder cancer. His study investigates the predictive capacity of an immunohistochemical (IHC) signature in pre-treatment TURBT specimens. His team's primar...
|
- Details
- Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
|
- Details
- Petros Grivas speaks with Vadim Koshkin about his groundbreaking research in urothelial cancer imaging. The focus is on Dr. Koshkin's abstract detailing the potential of Fibroblast-Associated Protein (FAP) imaging, a novel technique that targets cells present within the cancer, rather than the cancer cells themselves. The ongoing trial aims to enroll 80 patients with solid malignancies but shows p...
|
- Details
- Anne Schuckman and Alicia Morgans discuss the unique challenges and opportunities for women in urologic oncology. The two explore their own journeys in the field and provide suggestions on how young women seeking a career in urologic oncology can build their careers with confidence. Biographies: Anne K. Schuckman, MD, Director, LAC+USC Urologic Oncology, Keck Hospital of USC, USC Norris Cancer Hos...
|
- Details
- Stephen Williams sits down with Alicia Morgans to share some of the bladder cancer highlights from AUA 2022. Dr. Williams touches on a variety of topics in both muscle-invasive bladder cancer and non-muscle-invasive bladder cancer, including data from the QUILT study at UCLA, a pilot study on a comprehensive geriatric assessment tool at the University of Washington, the importance of psychological...
|
- Details
- In this discussion with Ashish Kamat, Tullika Garg presents on bladder cancer in the older adult population. Garg and Kamat discuss special considerations when diagnosing and treating this patient population and the differences in older cancer patients from their younger counterparts, due to geriatric conditions. Garg highlights that patients following cancer treatment, report, they have poorer ph...
|
- Details
- Barton Grossman joins Ashish Kamat in highlighting the 25th anniversary of the International Bladder Cancer Network (IBCN). The 2022 meeting is being held again in Barcelona, Spain, from September 29 – October 1. Dr. Grossman shares reflections on the cooperative efforts of the Bladder Cancer Marker Network of the National Cancer Institute (NCI), which focuses on developing and assessing biomarker...
|
